Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

计划入组 11 人 · 首次发布于 2021 年 9 月 5 日

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

计划入组 51 人 · 首次发布于 2017 年 12 月 19 日

SANCC: Clinical Trial Early Intervention

首次发布于 2019 年 5 月 15 日

Fanc-A gene therapy (Genethon)

Fanc-A gene therapy(Généthon)

Fanc-A gene therapy (Fanconi anemia)

FANCL CORPORATION

Japan

SRIDHAR FANCY & READYMEDS

India

Whole-Genome Sequencing Algorithm Outperforms Standard Tests for Predicting PARP Inhibitor Response

RETAIN Trial: Risk-Enabled Therapy Shows Promise in Bladder Cancer

Risk-Adapted Therapy Shows Promise in Muscle-Invasive Bladder Cancer